Survival Benefit of Pembrolizumab for Patients With Pancreatic Adenocarcinoma: A Case Series

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with 5-year survival rate of 10%. Evidence about pembrolizumab usage for PDAC is limited even though it is Food and Drug Administration (FDA)-approved for treatment of advanced pancreatic cancer with deficient mismatch repair expres...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Li, Singh, Vinit, Ricca, Anthony, Lee, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119368/
https://www.ncbi.nlm.nih.gov/pubmed/35655630
http://dx.doi.org/10.14740/jmc3918

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119368/
https://www.ncbi.nlm.nih.gov/pubmed/35655630
http://dx.doi.org/10.14740/jmc3918

Ejemplares similares